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Out-of-hospital cardiac arrest (OHCA) is a devastating disease process with neurological injury accounting for a disproportionate
amountofthemorbidityandmortalityfollowingreturnofspontaneouscirculation.Adearthofeﬀectivetreatmentstrategiesexists
for global cerebral ischemia-reperfusion (GCI/R) injury following successful resuscitation from OHCA. Emerging preclinical as
well as recent human clinical evidence suggests that activation of the complement cascade plays a critical role in the pathogenesis
of GCI/R injury following OHCA. In addition, it is well established that complement inhibition improves outcome in both global
andfocalmodelsofbrainischemia.DuetotheprofoundimpactofGCI/RinjuryfollowingOHCA,andtherelativelackofeﬀective
neuroprotectivestrategiesforthispathologicprocess,complementinhibitionprovidesanexcitingopportunitytoaugmentexisting
treatments to improve patient outcomes. To this end, this paper will explore the pathophysiology of complement-mediated GCI/R
injury following OHCA.
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1.Introduction
Ad e a r t ho fe ﬀective treatment strategies exist for global
cerebral ischemia-reperfusion (GCI/R) injury following suc-
cessful resuscitation from out-of-hospital cardiac arrest
(OHCA). OHCA is a devastating disease process with neu-
rological injury accounting for a disproportionate amount of
themorbidityandmortalityfollowingreturnofspontaneous
circulation (ROSC). The incidence of OHCA in industrial
countries ranges from 0.04 to 0.13% of the total population
per year, and only 11–48% of patients admitted to the
hospital are discharged in good neurologic condition. At
present, therapeutic hypothermia is the only neuroprotective
strategy shown to be eﬀective in well-controlled, prospective
trials of OHCA.
Complement, an important component of the innate
immune system, is known to play a central deleterious
role in multiple diverse disease processes. Eculizumab, a
monoclonal C5-antibody, is currently being used to treat
paroxysmal nocturnal hematuria, and pexelizumab, also a
C5-antibody, has been studied as adjunctive therapy in
ischemic heart disease [1, 2]. Emerging preclinical as well as
recent human clinical evidence also suggests that activation
of the complement cascade plays a critical role in the
pathophysiology of GCI/R injury following OHCA [3]. In
addition, it is well established that complement inhibition
improves outcome in both global and focal models of brain
ischemia [4–8]. Due to the profound impact of GCI/R injury
following OHCA, and the relative lack of eﬀective neuro-
protective strategies for this pathologic process, complement
inhibition provides an exciting opportunity to augment
existing treatment to improve patient outcomes. To this end,
this paper will explore the pathophysiology of complement-
mediated GCI/R injury following OHCA.
2. The Impactof out-of-Hospital CardiacArrest
Heart disease remains the leading cause of mortality in
the United States, and most frequently presents as sudden
out-of-hospital cardiac arrest (OHCA) [9]. Recent sources
indicate that approximately 166,000–310,000 Americans
experience an OHCA per year [10], with a variable number2 Mediators of Inﬂammation
undergoing resuscitation. Given this wide variability in
reported incidence, survival and outcome following OHCA
are diﬃcult to accurately assess [9]. A multitude of factors
has been shown to inﬂuence survival following OHCA,
including demographic, clinical, and treatment factors [11–
19] and attempts at inﬂuencing those factors that are mod-
iﬁable stand to potentially improve outcome. Brain injury
from global cerebral ischemia-reperfusion is a major factor
limiting the survival and functional recovery of patients after
resuscitation from OHCA. In most cases, survivors have
signiﬁcant impairment of consciousness and may eventually
progress to a persistent vegetative state [14]. The acute and
long-term care for these survivors comes with a staggering
cost to healthcare systems, patients’ families, and society as a
whole [20, 21].
Historically,survivalfollowingOHCAhasbeenpoor[22,
23], and although the morbidity and mortality of most car-
diovascular diseases have declined over the last 30 years [10]
there has been little improvement in survival post-OHCA
[24, 25]. Even in those patients that are resuscitated and
survive the initial insult, crippling neurological deﬁcits from
the global cerebral ischemia experienced during the arrest
are frequent. Survival for patients with an OHCA has been
reportedbetween1to31%withsigniﬁcantregionalvariation
[9, 10]. In fact, a recent large, prospective, multicenter obser-
vationalstudythroughoutNorthAmericademonstratedthat
only 7.9% of treated cardiac arrest patients survive until
discharge [9]. Multiple out-of-hospital factors, including
bystander cardiopulmonary resuscitation (CPR), time to
deﬁbrillation, and EMS experience have all been associated
with diﬀerences in survival after resuscitation [11, 26–28],
yet the eﬀect of hospital-based postresuscitation care on
outcomes has been largely ignored.
With advances in EMS deﬁbrillation programs, an
increasing number of patients survive to hospital admission
after OHCA. Of those patients, only 11–48% will be
discharged from the hospital with good neurologic outcome
[29]. Recently, in-hospital therapeutic hypothermia was
establishedasanoptiontoimproveneurologicoutcomeafter
OHCA[30,31].Anotherstudysuggestedthathemoﬁltration
to reduce inﬂammation after OHCA confers additional
survival beneﬁt, but this remains unproven [32].
3. TheInﬂammatoryResponsefollowingOHCA
With arrest of systemic and cerebral blood ﬂow for greater
than 5 minutes, a series of events is initiated, inciting
an inﬂammatory cascade resulting in signiﬁcant cerebral
injury [9, 10, 23, 33]. During and after cardiopulmonary
resuscitation, blood coagulation, platelet activation with
formation of thromboxane A2, and an alteration of soluble
E-selectin (sE-selectin) and P-selectin (sP-selectin) have
been described [34–36]. A postresuscitation syndrome,
characterized by hyperthermia, hypotension, and multiple
organ failure is likely the clinical expression of whole-body
ischemia-reperfusion (I/R) injury occurring after return
of spontaneous circulation [32, 37]. This syndrome is
associated with both complement activation and an intense
increase of various inﬂammatorymediators (IL-1, IL-6, IL-8,
and IL-10) as early as 3 hours after cardiac arrest, and thus
aﬀords potential targets for new treatments [37].
4. Complement and Cerebral Ischemia
The complement system, a phylogenetically conserved com-
ponent of the innate immune system, has been shown to
be signiﬁcantly involved in ischemia-reperfusion injury in
multiple organsystems,including thecentralnervous system
(CNS). The complement cascade contains more than 20
proteins and is involved in inﬂammation, opsonization, and
cytolysis in a wide range of diseases [38–44]. Complement
activation refers to the process of complement cascade
initiation and execution, which results in the production of
inﬂammatorymediators(C3a,C5a),theopsonizationofcells
with components (C3b) for recognition and phagocytosis by
macrophages, and the formation of lethal membrane attack
complexes (MAC, C5b-9) on target membranes [45].
Complement may be activated via one of several ways—
the classical, alternative, and lectin pathways. The classical
pathway is initiated by the binding of C1q to antibody-
antigen complexes while the lectin pathway begins when
pathogen-associated molecules become bound by lectin
proteins, such as MBL. Both of these pathways then catalyze
the cleavage of the C2 and C4 complement components
whichformaC3convertase.CleavedC3thenisincorporated
intoaC5convertasewhichleadstothecleavageofC5andthe
subsequent assembly of the MAC. The alternative pathway,
however, relies on spontaneous hydrolysis of C3 to form C3
and C5 convertases which lead to the formation of the MAC.
Also, there are several proteolytic enzymes such as elastases,
kallikrein, and thrombin, which can cleave C3 or C5, directly
[46–48]( Figure 1).
With regards to the central nervous system, activation
of complement has been implicated in the pathophysiology
of several distinct diseases, including multiple sclerosis [49],
development of vasospasm following aneurysmal subarach-
noid hemorrhage [50, 51], as well as stroke [5, 6, 52].
Increasing evidence demonstrates that cerebral ischemia
is followed by an acute systemic inﬂammatory response
of the host. The complement system plays an essential
and speciﬁc role in most pathological inﬂammatory events
(upregulation of adhesion molecules, neutrophil activation,
chemotaxis, expression of IL-8, and MCP-1 by endothe-
lial cells) which occur shortly after the ischemic insult
[53]. The essential role of complement activation in both
microvascular failure and direct neuronal cell death was
demonstrated in experimental animal models of permanent
and transient middle cerebral artery occlusion (MCAO)
through an increase in the expression of C3a and C5a
receptors and presence of C1q and C3 in the core of
the infarct [54, 55]. Our group subsequently demonstrated
signiﬁcant reduction of both infarct volume and oxidative
stress after transient MCAO in C3 knock-out mice [6].
Furthermore,treatmentofwild-typemicewithC3areceptor
antagonist (C3aRA) resulted in reduced stroke volumes and
improved neurologic function following transient cerebral
ischemia [5, 6]. Recently, Arumugam et al. reported that
C5-deﬁcient mice were signiﬁcantly protected from I/RMediators of Inﬂammation 3
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Figure 1: Complement cascade.
injury compared to wild-type littermates, and our group
supported this data by demonstrating that C5a receptor
antagonism reduces infarction volume in mice [56, 57]. In
further rodent experiments, broad spectrum complement
inhibitor cobra venom factor (CVF) [8, 56, 58], intravenous
immunoglobulin [56], C1-inhibitor [59, 60], and sCrry [61]
have all been shown to be protective against experimental
cerebral ischemia via complement inhibition.
Studies investigating complement activation following
human cerebral ischemia have been more limited. Pederson
et al. [54] and Mocco et al. [52] reported elevations of
SC5b-9 and C3a, respectively, in human stroke patients. In a
recent report, Szeplaki et al. further contributed to the body
of knowledge regarding complement activation in cerebral
ischemia by demonstrating early cleavage of multiple com-
plement components and an association between degree of
complement activation and clinical severity and unfavorable
outcome [53]. There is also growing recognition that com-
plement activation contributes to the pathogenesis of global
hypoxic-ischemic (HI) injury in both rodent models and in
human neonates. Circulating C3 is depleted following birth
asphyxia,anditwasrecentlydemonstratedthatpretreatment
with CVF signiﬁcantly reduced brain infarcts in p7 rats
subjectedtohypoxia-ischemia[45].Additionally,Hedtjarnet
al. noted that a number of genes involved in the complement
system were induced by HI in the immature brain, including
C 3 ar e c e p t o r ,C 5 ar e c e p t o r ,a n dC 1 q .S c h u l t ze ta l .[ 62]
also demonstrated signiﬁcant upregulation of C9 in human
infants who developed moderate to severe hypoxic-ischemic
encephalopathy and experimental animal work by our group
[7]d e m o n s t r a t e du p r e g u l a t i o no fC 1 qa n dC 3a f t e ra n
hypoxic-ischemic insult in mice. We further demonstrated
signiﬁcant protection in C1q knockout mice compared with
wild-type littermates, highlighting the central role of the
classical complement cascade in global cerebral hypoxic-
ischemic injury. However distinct neonatal physiology may
be, similar results have been found in studies of mature
animals in regards to complement activation in the setting
of transient global cerebral ischemia. Schafer et al. demon-
strated early and widespread upregulation of C1q expression4 Mediators of Inﬂammation
in brain microglia and secretion of functionally active C1q
into the CSF in response to experimentally induced global
cerebral ischemia in rats [63].
5. Ischemia/Reperfusion Injuryfollowing
out-of-Hospital CardiacArrest
Although reperfusion is essential for ultimate tissue survival,
it may exacerbate cerebral injury and thus presents a
treatment paradox [64]. As demonstrated above, activation
of complement plays a critical role in ischemia-reperfusion
injury leading to increased vascular permeability, activation
of the coagulation cascade, free-radical production, and
direct tissue damage [3, 65, 66]. Several models of ischemia-
reperfusion injury have implicated diﬀerent complement
activation pathways in this pathology, though less is known
how these pathways are initiated in ischemia-reperfusion
[7, 63, 67–71]( Table 1). Cardiac arrest and resuscitation
represent a whole-body I/R syndrome [3], yet the role of
complement in the pathophysiology of OHCA has only
recently begun to be elucidated. Pretreatment with the pro-
teinase inhibitor aprotinin and with heparin, both of which
reduce complement activation [72], increases survival after
cardiac arrest in rabbits [73]. In a swine model, aprotinin
enhanced the recovery of cerebral energy metabolism after
deep hypothermic circulatory arrest [74]. In the sole study
looking at complement levels following OHCA in humans,
Bottiger et al. demonstrated signiﬁcant systemic upregula-
tion of complement components C3a and SC5b-9 during
cardiopulmonary resuscitation and early reperfusion after
cardiac arrest [3]. The question remains, however, whether
complement activation after cardiac arrest in humans is
mechanistically involved with disease pathogenesis and
impacts neurologic outcome following OHCA [3].
6. Current Management of Global Cerebral
Ischemia-Reperfusion Injury
Recently, two trials demonstrated that induced hypothermia
confers a neuroprotective eﬀect in patients who were resusci-
tated from cardiac arrest [30, 31]. Clinical and experimental
results demonstrate a multifactorial neuroprotective eﬀect of
hypothermia during and after an ischemic insult by simul-
taneous suppression of several damaging pathways [29].
This has since become standard-of-care for select OHCA
patients in centers where therapeutic hypothermia is oﬀered.
The proposed mechanism of hypothermia’s protective eﬀect
has largely been attributed to its preservation of metabolic
substrates, alteration of cerebral blood ﬂow, and prevention
of excitatory amino acid accumulation [75, 76]. Other work,
however,hasshownthattheprofoundeﬀectsofhypothermia
on ameliorating cerebral injury are not fully explained by
these factors. Some have thus proposed that mild hypother-
mia also has anti-inﬂammatory eﬀects, although there are
conﬂicting results in the literature [76–78]. Recently, in an
elegantlydesignedrodentstudy,Callawayetal.demonstrated
that hypothermia following cardiac arrest does not alter
serum inﬂammatory markers, including TNF-alpha, MCP-1,
IL-2, IL-9, and IL-10, suggesting that the beneﬁcial eﬀects
Table 1: Complement pathways in ischemia-reperfusion injury.
Pathway Type of I-R Injury Study
Classical Brain Sch¨ afer et al. [63],
Ten et al. [7]
Skeletal muscle Weiser et al. [71]
Alternative Gastrointestinal Hart et al. [69]
Renal Thurman et al. [67],
Zhou et al. [70]
Lectin
Myocardial Jordan et al. [68]
Gastrointestinal Hart et al. [69]
Skeletal Muscle Weiser et al. [71]
I-R: ischemia-reperfusion.
of hypothermia do not arise from attenuation of the
inﬂammatory response [79]. Nevertheless, they conﬁrmed
a signiﬁcant acute upregulation of inﬂammatory markers
followingROSC.Analternateexplanationisthatthecerebral
inﬂammatory response following cardiac arrest may not be
accuratelyreﬂectedin serum measurements of inﬂammatory
biomarkers [79, 80]. The ﬁndings detailed above raise the
possibility of additional therapeutic beneﬁt from targeted
anticomplement and anti-inﬂammatory strategies combined
with hypothermia in the setting of OHCA.
7. Conclusion
While there exists little data concerning the activation of
complement in humans following OHCA, the importance
of complement activation, and in particular C3, has been
demonstrated repeatedly in the pathogenesis of ischemia-
reperfusion injury in both humans and various animal mod-
els [50, 51]. Selective complement inhibition, particularly
of C3, is therefore an attractive strategy for global cerebral
ischemia-reperfusion injury following OHCA, and may
thereby improve long-term outcomes. While complement
activation may be deleterious in the acute setting, it has
been shown to be involved in modulation of neurogenesis,
as well as the orderly clearance of apoptotic cell bodies,
and therefore may have long-term beneﬁcial eﬀects [81]. As
such, novel compounds that are able to reversibly inhibit
downstream complement components, such as C3 and C3a,
in the acute postischemic period may oﬀer the best chance
for a therapeutic beneﬁt in human OHCA patients.
References
[1] P. Hillmen, N. S. Young, J. Schubert, et al., “The complement
inhibitor eculizumab in paroxysmal nocturnal hemoglobin-
uria,” The New England Journal of Medicine, vol. 355, no. 12,
pp. 1233–1243, 2006.
[2] L. Testa, W. J. Van Gaal, R. Bhindi, et al., “Pexelizumab
in ischemic heart disease: a systematic review and meta-
analysis on 15,196 patients,” The Journal of Thoracic and
Cardiovascular Surgery, vol. 136, no. 4, pp. 884–893, 2008.
[3] B. W. Bottiger, J. Motsch, V. Braun, E. Martin, and M.
Kirschﬁnk, “Marked activation of complement and leukocytes
and an increase in the concentrations of soluble endothelialMediators of Inﬂammation 5
adhesion molecules during cardiopulmonary resuscitation
and early reperfusion after cardiac arrest in humans,” Critical
Care Medicine, vol. 30, no. 11, pp. 2473–2480, 2002.
[4] A. L. D’Ambrosio, D. J. Pinsky, and E. S. Connolly, “The role
of the complement cascade in ischemia/reperfusion injury:
implications for neuroprotection,” Molecular Medicine, vol. 7,
no. 6, pp. 367–382, 2001.
[ 5 ]A .F .D u c r u e t ,B .G .H a s s i d ,W .J .M a c K ,e ta l . ,“ C 3 a
receptor modulation of granulocyte inﬁltration after murine
focal cerebral ischemia is reperfusion dependent,” Journal of
Cerebral Blood Flow and Metabolism, vol. 28, no. 5, pp. 1048–
1058, 2008.
[6] J. Mocco, W. J. Mack, A. F. Ducruet, et al., “Complement
component C3 mediates inﬂammatory injury following focal
cerebral ischemia,” Circulation Research,v o l .9 9 ,n o .2 ,p p .
209–217, 2006.
[ 7 ]V .S .T e n ,S .A .S o s u n o v ,S .P .M a z e r ,e ta l . ,“ C 1 q - d e ﬁ c i e n c y
is neuroprotective against hypoxic-ischemic brain injury in
neonatal mice,” Stroke, vol. 36, no. 10, pp. 2244–2250, 2005.
[8] U. S. Vasthare, F. C. Barone, H. M. Sarau, et al., “Comple-
ment depletion improves neurological function in cerebral
ischemia,” Brain Research Bulletin, vol. 45, no. 4, pp. 413–419,
1998.
[9] G. Nichol, E. Thomas, C. W. Callaway, et al., “Regional
variation in out-of-hospital cardiac arrest incidence and
outcome,” Journal of the American Medical Association, vol.
300, no. 12, pp. 1423–1431, 2008.
[10] W. Rosamond, K. Flegal, K. Furie, et al., “Heart disease and
stroke statistics—2008 update: a report from the American
Heart Association Statistics Committee and Stroke Statistics
Subcommittee,” Circulation, vol. 117, no. 4, pp. e25–e146,
2008.
[11] L. Bergner, M. Bergner, A. P. Hallstrom, M. S. Eisenberg, and
L. A. Cobb, “Service factors and health status of survivors
of out-of-hospital cardiac arrest,” The American Journal of
Emergency Medicine, vol. 1, no. 3, pp. 259–263, 1983.
[12] R. J. Fairbanks, M. N. Shah, E. B. Lerner, K. Ilangovan,
E. C. Pennington, and S. M. Schneider, “Epidemiology and
outcomes of out-of-hospital cardiac arrest in Rochester, New
York,” Resuscitation, vol. 72, no. 3, pp. 415–424, 2007.
[13] M. T. Froehler and R. G. Geocadin, “Hypothermia for
neuroprotection after cardiac arrest: mechanisms, clinical
trialsandpatientcare,”JournaloftheNeurologicalSciences,vol.
261, no. 1-2, pp. 118–126, 2007.
[14] R. G. Geocadin and S. M. Eleﬀ, “Cardiac arrest resuscitation:
neurologic prognostication and brain death,” Current Opinion
in Critical Care, vol. 14, no. 3, pp. 261–268, 2008.
[15] M. C. Geraghty and M. T. Torbey, “Neuroimaging and
serologic markers of neurologic injury after cardiac arrest,”
Neurologic Clinics, vol. 24, no. 1, pp. 107–121, 2006.
[16] E. P. Hess, R. L. Campbell, and R. D. White, “Epidemiology,
trends, and outcome of out-of-hospital cardiac arrest of non-
cardiacorigin,”Resuscitation,vol.72,no.2,pp.200–206,2007.
[17] H. A. P¨ uttgen and R. Geocadin, “Predicting neurological
outcome following cardiac arrest,” Journal of the Neurological
Sciences, vol. 261, no. 1-2, pp. 108–117, 2007.
[18] H. Ros´ en, K. Stibrant Sunnerhagen, J. Herlitz, C. Blomstrand,
and L. Rosengren, “Serum levels of the brain-derived proteins
S-100 and NSE predict long-term outcome after cardiac
arrest,” Resuscitation, vol. 49, no. 2, pp. 183–191, 2001.
[19] A. L. Sherman, D. L. Tirschwell, P. J. Micklesen, W. T.
LongstrethJr.,andL.R.Robinson,“Somatosensorypotentials,
CSF creatine kinase BB activity, and awakening after cardiac
arrest,” Neurology, vol. 54, no. 4, pp. 889–894, 2000.
[20] W. A. Gray, R. J. Capone, and A. S. Most, “Unsuccessful
emergency medical resuscitation—are continued eﬀorts inthe
emergency department justiﬁed?” The New England Journal of
Medicine, vol. 325, no. 20, pp. 1393–1398, 1991.
[21] M. B. Hamel, R. Phillips, J. Teno, et al., “Cost eﬀectiveness of
aggressive care for patients with nontraumatic coma,” Critical
Care Medicine, vol. 30, no. 6, pp. 1191–1196, 2002.
[22] M. S. Eisenberg and T. J. Mengert, “Cardiac resuscitation,” The
New England Journal of Medicine, vol. 344, no. 17, pp. 1304–
1313, 2001.
[23] W. D. Rosamond, L. E. Chambless, A. R. Folsom, et al.,
“Trends in the incidence of myocardial infarction and in
mortality due to coronary heart disease, 1987 to 1994,” The
New England Journal of Medicine, vol. 339, no. 13, pp. 861–
867, 1998.
[24] J. Herlitz, A. B˚ ang, J. Gunnarsson, et al., “Factors asso-
ciated with survival to hospital discharge among patients
hospitalised alive after out of hospital cardiac arrest: change
in outcome over 20 years in the community of G¨ oteborg,
Sweden,” Heart, vol. 89, no. 1, pp. 25–30, 2003.
[25] T. D. Rea, R. M. Pearce, T. E. Raghunathan, et al., “Incidence
of out-of-hospital cardiac arrest,” American Journal of Cardiol-
ogy, vol. 93, no. 12, pp. 1455–1460, 2004.
[ 2 6 ]F .F r a n d s e n ,J .R .N i e l s e n ,L .G r a m ,C .F .L a r s e n ,H .R .I .
Jorgensen, and P. T. Hole Haghfelt, “Evaluation of intensiﬁed
prehospital treatment in out-of-hospital cardiac arrest: sur-
vival and cerebral prognosis. The Odense ambulance study,”
Cardiology, vol. 79, no. 4, pp. 256–264, 1991.
[27] G. Nichol, I. G. Stiell, A. Laupacis, B. Pham, V. J. De Maio, and
G.A.Wells,“Acumulativemeta-analysisoftheeﬀectivenessof
deﬁbrillator-capableemergencymedicalservicesforvictimsof
out-of-hospital cardiac arrest,” Annals of Emergency Medicine,
vol. 34, no. 4, part 1, pp. 517–525, 1999.
[28] J. G. van der Hoeven, J. de Koning, P. K. C. van der Weyden,
and A. E. Meinders, “Improved outcome for patients with
a cardiac arrest by supervision of the emergency medical
services system,” Netherlands Journal of Medicine, vol. 46, no.
3, pp. 123–130, 1995.
[29] M. Holzer, S. A. Bernard, S. Hachimi-Idrissi, R. O. Roine,
F. Sterz, and M. M¨ ullner, “Hypothermia for neuroprotection
after cardiac arrest: systematic review and individual patient
data meta-analysis,” Critical Care Medicine,v o l .3 3 ,n o .2 ,p p .
414–418, 2005.
[ 3 0 ]M .H o l z e r ,F .S t e r z ,J .M .D a r b y ,e ta l . ,“ M i l dt h e r a p e u t i c
hypothermia to improve the neurologic outcome after cardiac
arrest,” The New England Journal of Medicine, vol. 346, no. 8,
pp. 549–556, 2002.
[31] S. A. Bernard, T. W. Gray, M. D. Buist, et al., “Treatment
of comatose survivors of out-of-hospital cardiac arrest with
induced hypothermia,” The New England Journal of Medicine,
vol. 346, no. 8, pp. 557–563, 2002.
[32] I. Laurent, C. Adrie, C. Vinsonneau, et al., “High-volume
hemoﬁltration after out-of-hospital cardiac arrest: a random-
ized study,” Journal of the American College of Cardiology, vol.
46, no. 3, pp. 432–437, 2005.
[33] V. A. Negovsky and A. M. Gurvitch, “Post-resuscitation
disease—a new nosological entity. Its reality and signiﬁcance,”
Resuscitation, vol. 30, no. 1, pp. 23–27, 1995.
[34] S. Gando, S. Nanzaki, Y. Morimoto, S. Kobayashi, and O.
Kemmotsu, “Alterations of soluble L- and P-selectins during
cardiac arrest and CPR,” Intensive Care Medicine, vol. 25, no.
6, pp. 588–593, 1999.6 Mediators of Inﬂammation
[35] S. Gando, S. Nanzaki, Y. Morimoto, S. Kobayashi, and O.
Kemmotsu, “Out-of-hospital cardiac arrest increases solu-
ble vascular endothelial adhesion molecules and neutrophil
elastase associated with endothelial injury,” Intensive Care
Medicine, vol. 26, no. 1, pp. 38–44, 2000.
[36] A. Geppert, G. Zorn, G. Delle-Karth, et al., “Plasma concen-
trations of von Willebrand factor and intracellular adhesion
molecule-1 for prediction of outcome after successful car-
diopulmonary resuscitation,” Critical Care Medicine, vol. 31,
no. 3, pp. 805–811, 2003.
[37] C. Adrie, M. Adib-Conquy, I. Laurent, et al., “Successful
cardiopulmonaryresuscitationaftercardiacarrestasa“sepsis-
like” syndrome,” Circulation, vol. 106, no. 5, pp. 562–568,
2002.
[38] R. E. Chavez-Cartaya, G. P. DeSola, L. Wright, N. V. Jamieson,
and D. J. G. White, “Regulation of the complement cascade
by soluble complement receptor type 1: protective eﬀect in
experimental liver ischemiaandreperfusion,”Transplantation,
vol. 59, no. 7, pp. 1047–1052, 1995.
[39] K.E.Foreman,M.M.Glovsky,R.L.Warner,S.J.Horvath,and
P. A. Ward, “Comparative eﬀect of C3a and C5a on adhesion
molecule expression on neutrophils and endothelial cells,”
Inﬂammation, vol. 20, no. 1, pp. 1–9, 1996.
[40] J. Hill, T. F. Lindsay, F. Ortiz, C. G. Yeh, H. B. Hechtman,
and F. D. Moore Jr., “Soluble complement receptor type 1
ameliorates the local and remote organ injury after intestinal
ischemia-reperfusion in the rat,” The Journal of Immunology,
vol. 149, no. 5, pp. 1723–1728, 1992.
[41] J. H. Hill and P. A. Ward, “The phlogistic role of C3
leukotactic fragments in myocardial infarcts of rats.,” Journal
of Experimental Medicine, vol. 133, no. 4, pp. 885–900, 1971.
[42] M. Ikai, M. Itoh, T. Joh, Y. Yokoyama, N. Okada, and
H. Okada, “Complement plays an essential role in shock
followingintestinalischaemiainrats,”Clinical&Experimental
Immunology, vol. 106, no. 1, pp. 156–159, 1996.
[43] M. Pemberton, G. L. Anderson, V. Vetvicka, D. E. Justus, and
G. D. Ross, “Microvascular eﬀects of complement blockade
withsolublerecombinantCR1onischemia/reperfusioninjury
of skeletal muscle,” The Journal of Immunology, vol. 150, no.
11, pp. 5104–5113, 1993.
[ 4 4 ]M .R .Z a m o r a ,R .D .D a v i s ,S .H .K e s h a v j e e ,e ta l . ,“ C o m p l e -
mentinhibitionattenuateshumanlungtransplantreperfusion
injury: a multicenter trial,” Chest, vol. 116, supplement 1, p.
46S, 1999.
[45] R. M. Cowell, J. M. Plane, and F. S. Silverstein, “Complement
activation contributes to hypoxic-ischemic brain injury in
neonatal rats,” Journal of Neuroscience, vol. 23, no. 28, pp.
9459–9468, 2003.
[46] W. Vogt, B. Damerau, and B. Luhmann, “Complement acti-
vation in human lymph: modulation by the contact activation
systemandbyleukocytes,”InternationalArchivesofAllergyand
Applied Immunology, vol. 79, no. 4, pp. 423–433, 1986.
[47] M. Huber-Lang, J. V. Sarma, F. S. Zetoune, et al., “Generation
of C5a in the absence of C3: a new complement activation
pathway,” Nature Medicine, vol. 12, no. 6, pp. 682–687, 2006.
[48] R. C. Wiggins, P. C. Giclas, and P. M. Henson, “Chemotactic
activity generated from the ﬁfth component of complement
by plasma kallikrein of the rabbit,” Journal of Experimental
Medicine, vol. 153, no. 6, pp. 1391–1404, 1981.
[49] P. Gasque, S. K. Singhrao, J. W. Neal, et al., “The receptor
for complement anaphylatoxin C3a is expressed by myeloid
cells and nonmyeloid cells in inﬂamed human central nervous
system:analysisinmultiplesclerosisandbacterialmeningitis,”
The Journal of Immunology, vol. 160, no. 7, pp. 3543–3554,
1998.
[50] H. Kasuya and T. Shimizu, “Activated complement compo-
nentsC3aandC4aincerebrospinalﬂuidandplasmafollowing
subarachnoid hemorrhage,” Journal of Neurosurgery, vol. 71,
no. 5, part 1, pp. 741–746, 1989.
[51] W. J. Mack, A. F. Ducruet, Z. L. Hickman, et al., “Early plasma
complement C3a levels correlate with functional outcome
after aneurysmal subarachnoid hemorrhage,” Neurosurgery,
vol. 61, no. 2, pp. 255–260, 2007.
[52] J. Mocco, D. A. Wilson, R. J. Komotar, et al., “Alterations
in plasma complement levels after human ischemic stroke,”
Neurosurgery, vol. 59, no. 1, pp. 28–32, 2006.
[53] G. Sz´ eplaki, R. Szegedi, K. Hirschberg, et al., “Strong com-
plement activation after acute ischemic stroke is associated
with unfavorable outcomes,” Atherosclerosis, vol. 204, no. 1,
pp. 315–320, 2009.
[54] E.D.Pedersen,U.Waje-Andreassen,C.A.Vedeler,G.Aamodt,
a n dT .E .M o l l n e s ,“ S y s t e m i cc o m p l e m e n ta c t i v a t i o nf o l l o wi n g
human acute ischaemic stroke,” Clinical & Experimental
Immunology, vol. 137, no. 1, pp. 117–122, 2004.
[55] J. Van Beek, M. Bernaudin, E. Petit, et al., “Expression
of receptors for complement anaphylatoxins C3a and C5a
following permanent focal cerebral ischemia in the mouse,”
Experimental Neurology, vol. 161, no. 1, pp. 373–382, 2000.
[56] T. V. Arumugam, S.-C. Tang, J. D. Lathia, et al., “Intravenous
immunoglobulin (IVIG) protects the brain against experi-
mental stroke by preventing complement-mediated neuronal
cell death,” Proceedings of the National Academy of Sciences of
theUnitedStatesofAmerica,vol.104,no.35,pp.14104–14109,
2007.
[57] G. H. Kim, J. Mocco, D. K. Hahn, et al., “Protective eﬀect
of C5a receptor inhibition after murine reperfused stroke,”
Neurosurgery, vol. 63, no. 1, pp. 122–125, 2008.
[58] E. Figueroa, L. E. Gordon, P. W. Feldhoﬀ,a n dH .A .
Lassiter, “The administration of cobra venom factor reduces
post-ischemic cerebral injury in adult and neonatal rats,”
Neuroscience Letters, vol. 380, no. 1-2, pp. 48–53, 2005.
[59] N. Akita, H. Nakase, T. Kaido, et al., “Protective eﬀect of
C1 esterase inhibitor on reperfusion injury in the rat middle
cerebral artery occlusion model,” Neurosurgery, vol. 52, no. 2,
pp. 395–401, 2003.
[60] M. G. De Simoni, C. Storini, M. Barba, et al., “Neuroprotec-
tion by complement (C1) inhibitor in mouse transient brain
ischemia,” Journal of Cerebral Blood Flow and Metabolism, vol.
23, no. 2, pp. 232–239, 2003.
[61] C. Atkinson, H. Zhu, F. Qiao, et al., “Complement-dependent
P-selectin expression and injury following ischemic stroke,”
The Journal of Immunology, vol. 177, no. 10, pp. 7266–7274,
2006.
[62] S. J. Schultz, H. Aly, B. M. Hasanen, et al., “Complement com-
ponent9activation,consumption,andneuronaldepositionin
the post-hypoxic-ischemic central nervous system of human
newborn infants,” Neuroscience Letters, vol. 378, no. 1, pp. 1–
6, 2005.
[63] M. K.-H. Sch¨ afer, W. J. Schwaeble, C. Post, et al., “Comple-
ment C1q is dramatically up-regulated in brain microglia in
response to transient global cerebral ischemia,” The Journal of
Immunology, vol. 164, no. 10, pp. 5446–5452, 2000.
[64] P. Safar, W. Behringer, B. W. B¨ o t t i g e r ,a n dF .S t e r z ,“ C e r e -
bral resuscitation potentials for cardiac arrest,” Critical Care
Medicine, vol. 30, no. 4, supplement, pp. S140–S144, 2002.
[65] M. H. Crawford, F. L. Grover, W. P. Kolb, et al., “Complement
and neutrophil activation in the pathogenesis of ischemic
myocardial injury,” Circulation, vol. 78, no. 6, pp. 1449–1458,
1988.Mediators of Inﬂammation 7
[66] J. W. Homeister, P. Satoh, and B. R. Lucchesi, “Eﬀects of
complement activation in the isolated heart: role of the
terminal complement components,” Circulation Research, vol.
71, no. 2, pp. 303–319, 1992.
[67] J. M. Thurman, D. Ljubanovic, C. L. Edelstein, G. S. Gilkeson,
and V. M. Holers, “Lack of a functional alternative com-
plement pathway ameliorates ischemic acute renal failure in
mice,” The Journal of Immunology, vol. 170, no. 3, pp. 1517–
1523, 2003.
[68] J. E. Jordan, M. C. Montalto, and G. L. Stahl, “Inhibition
of mannose-binding lectin reduces postischemic myocardial
reperfusion injury,” Circulation, vol. 104, no. 12, pp. 1413–
1418, 2001.
[69] M. L. Hart, M. C. Walsh, and G. L. Stahl, “Initiation of
complement activation following oxidative stress. In vitro and
in vivo observations,” Molecular Immunology, vol. 41, no. 2-3,
pp. 165–171, 2004.
[70] W. Zhou, C. A. Farrar, K. Abe, et al., “Predominant role for
C5b-9 in renal ischemia/reperfusion injury,” The Journal of
Clinical Investigation, vol. 105, no. 10, pp. 1363–1371, 2000.
[71] M.R.Weiser,J.P.Williams,F.D.MooreJr.,etal.,“Reperfusion
injury of ischemic skeletal muscle is mediated by natural
antibody and complement,” Journal of Experimental Medicine,
vol. 183, no. 5, pp. 2343–2348, 1996.
[72] J. M. Weiler, R. E. Edens, R. J. Linhardt, and D. P. Kapelanski,
“Heparin and modiﬁed heparin inhibit complement activa-
tion in vivo,” The Journal of Immunology, vol. 148, no. 10, pp.
3210–3215, 1992.
[73] W. Gaszynski, “The use of protease inhibitor (trasylol) and
heparin in cardiorespiratory resuscitation. I. Studies of the
blood clotting system,” Anaesthesia Resuscitation and Intensive
Therapy, vol. 3, no. 2, pp. 125–134, 1975.
[74] M. Aoki, R. A. Jonas, F. Nomura, et al., “Eﬀects of aprotinin
on acute recovery of cerebral metabolism in piglets after
hypothermic circulatory arrest,” Annals of Thoracic Surgery,
vol. 58, no. 1, pp. 146–153, 1994.
[75] R. Busto, M. Y.-T. Globus, W. D. Dietrich, E. Martinez, I.
Valdes, and M. D. Ginsberg, “Eﬀect of mild hypothermia on
ischemia-induced release of neurotransmitters and free fatty
acids in rat brain,” Stroke, vol. 20, no. 7, pp. 904–910, 1989.
[ 7 6 ]M .A .Y e n a r ia n dH .S .H a n ,“ I n ﬂ u e n c eo fh y p o t h e r m i ao n
post-ischemic inﬂammation: role of nuclear factor kappa B
(NFκB),” Neurochemistry International, vol. 49, no. 2, pp. 164–
169, 2006.
[77] J. Inamasu, S. Suga, S. Sato, et al., “Post-ischemic hypothermia
delayed neutrophil accumulation and microglial activation
following transient focal ischemia in rats,” Journal of Neuroim-
munology, vol. 109, no. 2, pp. 66–74, 2000.
[78] J. Inamasu, S. Suga, S. Sato, et al., “Intra-ischemic hypother-
mia attenuates intercellular adhesion molecule-1 (ICAM-1)
and migration of neutrophil,” Neurological Research, vol. 23,
no. 1, pp. 105–111, 2001.
[79] C. W. Callaway, J. C. Rittenberger, E. S. Logue, and M. J.
McMichael, “Hypothermia after cardiac arrest does not alter
serum inﬂammatory markers,” Critical Care Medicine, vol. 36,
no. 9, pp. 2607–2612, 2008.
[80] A. I. Qureshi, “Serum inﬂammatory markers after postcardiac
arrest resuscitation: surrogate markers of eﬃcacy, therapeutic
targets, or innocent bystanders,” Critical Care Medicine, vol.
36, no. 9, pp. 2698–2699, 2008.
[81] Y.Rahpeymai,M.A.Hietala,U.Wilhelmsson,etal.,“Comple-
ment: a novel factor in basal and ischemia-induced neurogen-
esis,” EMBO Journal, vol. 25, no. 6, pp. 1364–1374, 2006.